A. Burak Ozbay, MBA, PhD1, Mallik Greene, PhD2, Timo Pew, MS2, Quang Le, PharmD, PhD3, Michael Dore, MD4, A Mark Fendrick, MD5, Paul Limburg, MD, MPH6 1Exact Sciences, Lake Forest, IL; 2Exact Sciences, Madison, WI; 3Exact Sciences Corporation, Madison, WI; 4Durham, NC; 5University of Michigan, Ann Arbor, MI; 6Exact Sciences, Rochester, MN
Introduction: The multi-target stool DNA test (mt-sDNA) is a guideline-recommended, at-home CRC screening option for average-risk individuals. The test includes access to 24/7/365 navigation support (in 240 languages) for both patients and providers. To improve patient navigation accompanying mt-sDNA, we personalized the standard outreach program (PO) by including the name of the patient’s health system on the communications that were sent to the patient. The primary objective was to compare mt-sDNA adherence rates between patients receiving PO and those receiving standard outreach (SO).
Methods: Individuals aged 45 years and older with a valid mt-sDNA order between May 4, 2023, and July 27, 2023, were assigned to PO or SO only. Patient characteristics were matched prior to assigning them to the groups. Patient adherence was defined as return of the mt-sDNA test kit and a successful test result within 180 days from the initial shipment.
Results: Of 37,005 patients included in the study, 11,159 received PO and 25,846 received SO. Overall adherence to mt-sDNA was significantly higher with PO than SO (63% vs 61.1%, p< 0.001). Personalized outreach had a statistically significant impact on mt-sDNA adherence among patients aged 65-75 years (65.1% vs 62.1%, p=0.003), patients new to mt-sDNA (65.5% vs 63.6%, p=0.004), females (63.4% vs 61.3%, p=0.004), patients from metropolitan areas (62.8% vs 60.8%, p< 0.001), patients preferred language is English (65.6% vs 63.7%, p=0.031) and patients with a median household income of $50K to $75K (62.9% vs 60.3%, p=0.003).
Discussion: Patient’s receiving personalized outreach to support their prescribed mt-sDNA based CRC screening showed statistically significantly higher screening adherence than those receiving standard outreach. This study highlights the importance of tailoring patient navigation programs to better motivate completion of average-risk CRC screening.
Disclosures:
A. Burak Ozbay: Exact Sciences – Employee, Stock Options.
Mallik Greene: exact sciences – Employee.
Timo Pew: Exact Sciences – Employee, Stock-publicly held company(excluding mutual/index funds).
Quang Le: Exact Sciences – Employee.
Michael Dore indicated no relevant financial relationships.
A Mark Fendrick: Exact Sciences – Advisory Committee/Board Member, Consultant.
Paul Limburg: Exact Sciences Corporation – Consultant, Employee, Stock-publicly held company(excluding mutual/index funds).
A. Burak Ozbay, MBA, PhD1, Mallik Greene, PhD2, Timo Pew, MS2, Quang Le, PharmD, PhD3, Michael Dore, MD4, A Mark Fendrick, MD5, Paul Limburg, MD, MPH6. P2120 - Impact of Personalized Patient Outreach on Multi-Target Stool DNA Test Adherence in a Large Colorectal Cancer Screening Population, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
